VEGF and bFGF Gene Polymorphisms in Patients with Non-Hodgkins LymphomaReportar como inadecuado

VEGF and bFGF Gene Polymorphisms in Patients with Non-Hodgkins Lymphoma - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

BioMed Research InternationalVolume 2013 2013, Article ID 159813, 6 pages

Research Article

Department of Haematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, L. Pasteura 4, 50-367 Wroclaw, Poland

Department of Internal, Occupational Diseases and Hypertension, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland

Laboratory of Clinical Immunogenetics and Pharmacogenetics, L. Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, R. Weigla 12, 53-114 Wroclaw, Poland

Received 14 April 2013; Revised 26 June 2013; Accepted 3 July 2013

Academic Editor: Konstantinos Papatheodorou

Copyright © 2013 Tomasz Wróbel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Angiogenesis and lymphangiogenesis are important in the proliferation and survival of the malignant hematopoietic neoplasms, including non-Hodgkin’s lymphomas NHLs. Vascular endothelial growth factor VEGF and basic fibroblast growth factor bFGF play an important role in the initiation of angiogenesis. Both VEGF and bFGF have been reported to have prognostic significance in NHL. The present study aimed to determine an association between the VEGF and bFGF gene polymorphisms and disease susceptibility and progression. VEGF rs3025039; 936 C>T and bFGF rs308395, −921 G>C variants were determined in 78 NHL patients and 122 healthy individuals by PCR-RFLP technique. The presence of the VEGF 936T allele was found to significantly associate with worse prognosis of the disease expressed by the highest International Prognostic Index IPI 0.41 versus 0.20, for IPI 4 among patients having and lacking the T allele. The VEGF 936T variant was also more frequent among patients with IPI 4 than in controls OR = 3.37, . The bFGF −921G variant was more frequently detected among patients with aggressive as compared to those with indolent histological subtype 0.37 versus 0.18, and healthy individuals 0.37 versus 0.19, OR = 2.51, . These results imply that VEGF and bFGF gene polymorphisms have prognostic significance in patients with NHL.

Autor: Tomasz Wróbel, Grzegorz Mazur, Justyna Dzietczenia, Katarzyna Gębura, Kazimierz Kuliczkowski, and Katarzyna Bogunia-Kubik



Documentos relacionados